Berkshire Asset Management LLC PA raised its stake in Johnson & Johnson (NYSE:JNJ) by 0.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 199,426 shares of the company’s stock after purchasing an additional 513 shares during the quarter. Johnson & Johnson makes up about 2.9% of Berkshire Asset Management LLC PA’s portfolio, making the stock its 4th biggest holding. Berkshire Asset Management LLC PA’s holdings in Johnson & Johnson were worth $25,927,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Harding Loevner LP acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. lifted its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $177,000. Institutional investors own 65.71% of the company’s stock.
Several analysts recently weighed in on the company. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a report on Thursday, January 11th. Stifel Nicolaus lifted their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Citigroup lifted their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Jefferies Group raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the stock from $145.00 to $157.00 in a report on Wednesday, October 11th. Finally, Argus lifted their price target on Johnson & Johnson from $145.00 to $165.00 and gave the stock a “positive” rating in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $145.94.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.68 EPS. equities research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.28%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
ILLEGAL ACTIVITY WARNING: This story was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3146912/johnson-johnson-jnj-is-berkshire-asset-management-llc-pas-4th-largest-position.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.